JPRN-jRCT2031210387招募中1 期
A Phase I/II Study of necitumumab + carboplatin + nab-paclitaxel + pembrolizumab for previously untreated advanced squamous non-small cell lung cancer study - NEXUS
Seike Masahiro0 个研究点目标入组 60 人开始时间: 2021年10月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old（—）
- 性别
- All
入选标准
- •(1)Lung squamous cell carcinoma confirmed by histology or cytology
- •(2)Patients with Clinical Stage 3B, 3C or 4A-4B/Postoperative Recurrent Cases Unamenable to Radical Radiation
- •*Practice for Lung Cancer (January 2017 [8th edition]). Japanese Lung Cancer Society/Edition
- •(3)Patients with measurable lesions based on RECISTVer 1.1.
- •*It is not mandatory in phase 1 trials.
- •(4)Patients with no history of chemotherapy treatment for squamous cell carcinoma of the lung using cytotoxic anticancer agents or agents with EGFR inhibitory activity, or treatment with immune checkpoint inhibitors
- •*Preoperative and postoperative adjuvant chemotherapy, excluding EGFR inhibitors, is acceptable if 6 months have passed since the last dose.
- •*Pleurodesis is acceptable.
- •(5)Patients aged 20 years and younger than 80 years at the time of informed consent
- •(6)Patients with an ECOG performance status (PS) between 0 and 1.
- •(7)Patients who meet the following criteria for major organ function within 14 days before enrollment (the same day of the week before 2 is allowed based on the date of enrollment)
- •In addition, if more than one test result exists within this period, the most recent one to be registered shall be adopted, and in addition, it shall be verified that blood transfusion and hematopoietic factor products, etc. have not been administered within 14 days before the test day.
- •1)Neutrophil count: 1500/microL or higher
- •2)Hemoglobin: 10.0g/dL or higher
- •3)Platelet count: 100,000/mm3 or higher
- •4)AST: 100U/L or less or 2.5 times or less the upper limit of the institutional standard value (5 times or less if the patient has liver metastasis)
- •5)ALT: 100U/L or less or 2.5 times or less the upper limit of the institutional standard (5 times or less if liver metastasis is present)
- •6)Total bilirubin: 1.5mg/dl or less or 1.5 times or less the upper limit of the institutional standard
- •(3 times or less if liver metastasis or Gilbert's syndrome is present)
- •7)Serum creatinine clearance: 45 ml/min (calculated) or more
- •8)SpO2>=93 %
- •(8)Patients who have been fully explained about the contents of the study and have given their written consent.
排除标准
- •(1)Patients with interstitial lung diseases (ILDs), drug-induced ILDs, a history of radiation pneumonitis requiring steroidal treatment, or active ILD.
- •(2)Patients with brain metastasis or spinal cord compression that is not clinically stable.
- •However, patients who do not require steroids and are neurologically stable for at least 2 weeks after completion of definitive and steroid therapy will not be excluded.
- •(3)Patients who have received radiation to the primary lesion or the evaluated lesion.
- •*Patients will not be excluded if they have received palliative irradiation for the primary lesion or for lesions other than the evaluated lesion for at least 2 weeks.
- •(4)Patients with serious complications (uncontrolled pulmonary, hepatic, renal disease, etc.)
- •(5) Patients with active hepatitis B.
- •*HBV DNA should be measured if HBsAg positive, HBsAb positive, and HBc Ab positive.
- •HBV DNA positivity is excluded.
- •(6) A man unwilling to contraceptive.
- •Or pregnant, lactating, pregnant or unwilling women with a positive pregnancy test or unwilling to use contraception.
- •*However, the following patients may be enrolled.
- •Women aged 50 years or older and those who have experienced amenorrhea for 12 months or more.
- •(In cases where exogenous hormone therapy was used, amenorrhea should be present for at least 12 months after discontinuation of all exogenous hormone therapy.)
- •Among women younger than 50 years, amenorrhea for at least 12 months (more than 12 months after discontinuation of exogenous hormone treatment), luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels within the range of postmenopausal at the center reference level, and considered postmenopausal.
- •Women who have undergone permanent sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy (tubal ligation is not possible)
- •(7)Patients with intractable nausea and vomiting, chronic gastrointestinal disease, dysphagia of the preparation, and total gastrectomy.
- •(8)Patients of pleural effusion requiring drain drainage, pericardial effusion, and ascites.
- •*However, patients with stable symptoms after drainage can be enrolled.
- •(9)Patients contraindicated for necitumumab, carboplatin, nab-paclitaxel, and pembrolizumab.
- •(10)Patients with synchronous double cancers or metachronous double cancers with disease-free interval of 5 years or less.
- •*Carcinoma in situ (carcinoma in situ) or intramucosal carcinoma that is judged to be cured by local treatment is not excluded.
- •(11)Patients in which ingestion is not possible.
- •(12)Patients in which life expectancy is expected to be 12 weeks or less.
- •(13)Persons involved in the protocol and conduct of the study (principal investigators, subinvestigators, employees or staff of the participating medical organizations)
- •(14)Patients who are receiving concomitant medications or herbal supplements with known potent inducing effects on CYP3A4 and are unable to discontinue use at least 3 weeks prior to the first dose of study Drugs used in the Clinical Trial.
- •(15)Patients with a history of hypersensitivity to necitumumab (or drugs of the same chemical structure or class as necitumumab), carboplatin or nab-paclitaxel or pembrolizumab, or vehicle for these drugs.
- •(16)Patients with conjunctivitis requiring treatment, hypomagnesemia, and skin disorders.
- •(17)Patients with hypertension uncontrolled by drug treatment (defined as systolic pressure of 150mmHg or higher or diastolic pressure of 90mg or higher) and patients with active bleedi
研究者
相似试验
招募中
1 期
A Phase 1/2 Study of Necitumumab plus Osimertinib for Advanced Non-small Cell Lung Cancer with EGFR-mutatioJPRN-jRCT2021210079Maemondo Makoto92
进行中（未招募）
2 期
Phase II study of necitumumab and pembrolizumab in patients with PD-L1 high-expressing non-small-cell lung cancerPD-L1 high-expressing non-small-cell lung cancernon-small cell lung cancerJPRN-jRCT2031200248Horiike Atsushi50
招募中
2 期
Phase II trial of Nedaplatin/S-1/Cetuximab combination therapy for Recurrence or Metastatic Squamous cell carcinoma of the Head and NeckRecurrence or Metastatic Squamous cell carcinoma of the Head and NeckJPRN-UMIN000011497Kinki University Faculty of Medicine, Department of Medical Oncology40
进行中（未招募）
1 期
ivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade gliomaewly diagnosed High-Grade Gliomas (HGG)MedDRA version: 20.0 Level: PT Classification code 10065443 Term: Malignant glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10018338 Term: Glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002688-24-FRGustave Roussy40
尚未招募
1 期
Phase I/II trial of S-1+Nedaplatin+Cetuximab for recurrent/metastatic head and neck squamous cell carcinomahead and neck squamous cell carcinomaJPRN-UMIN000012074Kyorin University School of Medicine, Department of Otolaryngology30